Status: Recruiting
A Phase 3 Study of NTLA-2001 in ATTRv-PN
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
Participants needed: 60
Trial details
Phase: Phase 3Age: 18-85Biological sex: AllType: InterventionalSponsor: Intellia TherapeuticsUpdated: Apr 16, 2026Locations: 14
Eligibility criteria
Diagnosis of ATTRv-PN [+1]
Other causes of amyloidosis (amyloidosis caused by non-TTR protein) [+9]